Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 8/20 | 0.43 |
| ▸ | KRAS | P01116 | 2/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28726566 | 0.82 | HTT (0.61) | CNR1CNR2EGFRKRASSOS1 | |
| SCHEMBL28726565 | 0.82 | HTT (0.61) | CNR1CNR2EGFRKRASSOS1 | |
| SCHEMBL29481385 | 0.82 | HTT (0.61) | CNR1CNR2EGFRKRASSOS1 | |
| SCHEMBL22745159 | 0.81 | CNR1 (0.52) | CNR1CNR2EGFRKRASSOS1 | |
| SCHEMBL29427613 | 0.80 | EGFR (0.53) | CNR1CNR2EGFRKRASSOS1 | |
| SCHEMBL28713734 | 0.80 | EGFR (0.53) | CNR1CNR2EGFRKRASSOS1 | |
| SCHEMBL24673910 | 0.80 | EGFR (0.53) | CNR1CNR2EGFRKRASSOS1 | |
| SCHEMBL22745242 | 0.79 | GALR3 (0.67) | CNR1CNR2EGFRKRASSOS1 | |
| SCHEMBL24674199 | 0.79 | P2RX3 (0.42) | — | |
| SCHEMBL28713809 | 0.79 | P2RX3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | CNR1 206/4885CNR2 193/4885EGFR 1611/4885 |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | CNR1 206/4885CNR2 193/4885EGFR 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.